Project title: Chemical biology for drugging undruggable targets

• Acronyme: ChemBioDrug


• Registration number: CZ.02.1.01/0.0/0.0/16_019/0000729


• Brief description: The objective of a research agenda conceived in this way is the development of new potential therapeutics of cancers, viral diseases and metabolic disorders on the principle of specific inhibition of so-called "undruggable" interactions of biomacromolecules, on which classical medicinal chemistry cannot reach. The research will be focused on three key types of biomolecular interactions: protein-protein; protein-membrane and protein-DNA or protein-RNA. With the use of a multidisciplinary approach combining the structurally- and molecularly biological characterization of the target biomacromolecules and their interactions, bioinformatics and molecular modelling, design and chemical synthesis of a series of potential inhibitors (including libraries of sequences of modified peptides and oligonucleotides), detailed testing of the inhibition of targeted biomolecular interactions, or in vitro selection methods of their identification from the libraries of sequences, and study of the cytostatic and antiviral activities, or physiological effect of the tested substances, substances with the highest activity and lowest toxicity will be selected for further preclinical studies.

  
  Within the project, research teams will be particularly enriched with newly acquired local and foreign talented doctoral candidates, post-docs and junior researchers. Project will ensure the development of the existing infrastructure mainly in the area of theoretical calculations and modelling, experimental studies of protein interactions, automatic testing of substances, microscopy, sequencing RNA, DNA and in the area of chromatographic separation. Project activities will support the international research cooperation with world recognized research institutions: Catholic University in Leuven, Johns Hopkins University and the pharmaceutical company Gilead Sciences, Inc.



• Realisation schedule: 1. 1. 2018 - 31. 12. 2022


• Principal investigator: Prof. Ing. Michal Hocek, CSc. DSc.


• Beneficiary: ÚOCHB AV ČR v.v.i.


• Project outcomes

Project title: UOCHB Mobility

• Registration number: CZ.02.2.69/0.0/0.0/16_027/0008477


• Brief description: The aim of the project is the establishment and the realization of the international research cooperation by means of creating the attractive research job positions for perspective candidates from abroad and by means of supporting the participation of current research staff in the internships at renowned research institutions abroad. Mutual exchange of experience, good research practice, enhancement of research staff knowledge, abilities and skills will ensure the appropriate conditions for further development of the excellent research in the IOCB.


• Realisation schedule: 22. 1. 2018 - 31. 3. 2021


• Principal investigator: Ing. Iva Pichová, CSc.


• Beneficiary: ÚOCHB AV ČR v.v.i.


• Project outcomes

Project title: UOCHB MSCA Mobility

• Registration number: CZ.02.1.01/0.0/0.0/16_025/0007444


• Brief description: The aim of the project is the establishment and the realization of the international research cooperation by means of supporting the participation of research staff in the internships at renowned research institutions abroad. This project focused at the researchers that did not succeed in H2020 MSCA IF 2016 call. The mutual Exchange of experience, good research practice the enhancement of research staff knowledge, abilities and skills as well as networking with research institutions across the world will ensure appropriate conditions for further development of the excellent research in the IOCB.


• Realisation schedule: 22. 1. 2018 - 31. 3. 2021


• Principal investigator: Ing. Iva Pichová, CSc.


• Beneficiary: ÚOCHB AV ČR v.v.i.


• Project outcomes

Project title: PharmaBrain

• Registration number: CZ.02.2.69/0.0/0.0/17_050/0008490


• Brief description: The project is aimed at the research of the glutamatergic neurotransmitter system that controls wide range of brain processes. This system also takes part in normal brain development, while the dysfunction of this system plays the key role in many neuropsychiatric diseases. The project is focused on its role in clinical practice as well as in experimental models. The research in this area has a long tradition in all participating institutions and also a high reputation among the professionals worldwide.


• Realisation schedule: 1. 1. 2018 - 31. 12. 2022


• Principal investigator: RNDr. Eva Kudová, Ph.D.


• Beneficiary: Národní ústav duševního zdraví (NÚDZ)


• Partneři projektu s finančním příspěvkem:
  - Institute of Physiology CAS (IPHYS)
  - Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague)
  - University of Hradec Králové (UHK)
  - 3rd Faculty of Medicine Charles University


• Project outcomes